Re: Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs (Friedrichson et al., Critical Care, January 2021)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Re: Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs (Friedrichson et al., Critical Care, January 2021) ; volume:25 ; number:1 ; day:26 ; month:3 ; year:2021 ; pages:1-2 ; date:12.2021
Critical care ; 25, Heft 1 (26.3.2021), 1-2, 12.2021
- Creator
-
Warren, Alex
Camporota, Luigi
Ledot, Stephane
Scott, Ian
Vuylsteke, Alain
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13054-021-03529-1
- URN
-
urn:nbn:de:101:1-2021051021431636710012
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2024, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Warren, Alex
- Camporota, Luigi
- Ledot, Stephane
- Scott, Ian
- Vuylsteke, Alain
- SpringerLink (Online service)
Other Objects (12)
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Optimierung der ECMO-Therapie bei schwerem ARDS
To prone or not to prone ARDS patients on ECMO
Quo vadis ECMO?
ECMO in Poisoning
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review
Influenza-A/H1N1-Infektion – Welchen Nutzen hat eine ECMO bei schwerem ARDS?
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Optimierung der ECMO-Therapie bei schwerem ARDS
To prone or not to prone ARDS patients on ECMO
Quo vadis ECMO?
ECMO in Poisoning
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review
Influenza-A/H1N1-Infektion – Welchen Nutzen hat eine ECMO bei schwerem ARDS?
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs
Optimierung der ECMO-Therapie bei schwerem ARDS
To prone or not to prone ARDS patients on ECMO
Quo vadis ECMO?
ECMO in Poisoning
Hämolyse bei Patientinnen und Patienten mit ARDS und Therapie mit ECMO
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Use of ECMO in ARDS: does the EOLIA trial really help?
ECMO is associated with decreased hospital mortality in COVID-19 ARDS
Mesenchymal stem cells-based therapies for severe ARDS with ECMO: a review